Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes.

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

Among patients with type-2 diabetes (T2D) requiring insulin therapy, automated insulin delivery (AID) resulted in a greater ...

Another AID system, the Omnipod 5 ... in a 2:1 ratio to receive the AID with Tandem’s t:slim X2 insulin pump with Control-IQ+ technology in conjunction with a Dexcom G6 CGM, or to continue ...

Beck and colleagues from the JAEB Center for Health Research, Tampa, Florida, USA, highlight the rapid onset of action of inhaled Technosphere Insulin (TI, Afrezza) compare ...

The AID system used in the study was Tandem Diabetes Care's t:slim X2 insulin pump with Control-IQ+ technology, used in conjunction with a Dexcom G6 CGM sensor that can be used with NovoLog or ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes using an automated ...

The Global Insulin Pump Market achieved a valuation of $5.90 Billion in 2024 and is anticipated to exceed $14.49 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 8.55% during the ...

Automated insulin delivery systems have demonstrated benefits ... which received the t:slim X2 insulin pump with Control-IQ+ technology and a Dexcom G6 sensor, or the control group, which ...